This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SR One | |
|---|---|
| Name | SR One |
| Type | Private venture capital firm |
| Founded | 1985 |
| Headquarters | Menlo Park, California |
| Industry | Venture capital, Biotechnology |
| Products | Venture capital, growth financing |
| Assets | Estimated assets under management |
SR One is a venture capital firm specializing in financing biotechnology and life sciences companies. Founded by former executives of GSK's corporate venture arm, the firm focuses on supporting translational research, product development, and company formation across therapeutics, platform technologies, and medical technologies. Its activities bridge academic research at institutions such as Stanford University and University of California, San Francisco with commercial development in the Bay Area and global biopharma hubs like Boston, San Diego, and Cambridge, UK.
SR One traces origins to the corporate venture activities of SmithKline Beecham and its successor GlaxoSmithKline in the 1980s and 1990s, when pharmaceutical firms began creating dedicated investment arms to capture innovation from biotechnology startups. Early firm leaders who left Glaxo reorganized the corporate venture group into an independent firm in the early 2000s, taking with them relationships to academic medical centers and research institutes that produce spinouts. Over subsequent decades, the firm navigated cycles in the biotech sector, participating in financings through the dot-com aftermath, the 2008 financial crisis, and the 2010s surge in biologics and gene therapies. SR One engaged with regulatory developments at U.S. Food and Drug Administration and reimbursement shifts influenced by Centers for Medicare & Medicaid Services policies while following scientific advances from groups at Massachusetts Institute of Technology and Harvard Medical School.
The firm operates as a private limited partnership with a team of investment professionals, scientific advisors, and operating partners drawn from pharmaceutical companies such as Pfizer, Roche, and Novartis, and from academic institutions including Johns Hopkins University and University of Pennsylvania. Governance includes a board of partners and advisory committees that evaluate preclinical portfolios against metrics used by regulators like European Medicines Agency. Unlike captive corporate venture funds tied to a single parent company—examples include the historical arms of Eli Lilly and Johnson & Johnson—this firm is structured to raise independent funds from institutional limited partners such as pension funds, endowments, and family offices. Headquartered in Menlo Park, California, the firm maintains networks in major biotech clusters including Cambridge, Massachusetts and connections to incubators like BioLabs and accelerators such as Y Combinator-adjacent life-science programs.
The firm targets early-stage and growth-stage investments across therapeutic modalities—small molecules, biologics, cell and gene therapy—and platform technologies including drug discovery tools, diagnostics, and synthetic biology. Investment decisions leverage expertise from translational scientists affiliated with Broad Institute and clinical development leaders experienced with Phase I trials and Phase III trials. Due diligence emphasizes intellectual property portfolios with filings at national patent offices and freedom-to-operate analyses informed by prior litigation such as disputes involving Amgen and Genentech. Portfolio construction balances high-risk, high-reward bets in novel modalities with later-stage financings where regulatory pathways at the FDA and reimbursement prospects via Centers for Medicare & Medicaid Services are clearer. The firm also collaborates with corporate partners in strategic licensing and co-development deals with companies like Sanofi and Bristol-Myers Squibb.
Over its history the firm has invested in companies that pursued approvals from regulators including the U.S. Food and Drug Administration and launched products in markets shaped by payers like National Health Service (England). Notable portfolio companies have included innovators in oncology, rare disease, and infectious disease therapeutics, some achieving acquisitions by major pharmaceutical players such as AstraZeneca and Merck & Co.. Other exits involved public listings on exchanges in New York Stock Exchange and NASDAQ, enabling liquidity events for limited partners and funding subsequent rounds for remaining portfolio companies. The firm’s track record encompasses both trade sales and initial public offerings alongside secondary transactions with crossover investors such as OrbiMed and Perceptive Advisors.
The firm has influenced the translation of academic discoveries into commercial therapeutics through seed and series A investments that spun out technologies from institutions including University of California, Berkeley, Cold Spring Harbor Laboratory, and Salk Institute for Biological Studies. By financing platform companies in areas like CRISPR-related tools and oligonucleotide therapeutics, it contributed to the ecosystem enabling follow-on investments by firms such as Sequoia Capital and ARCH Venture Partners. The firm’s involvement in cross-disciplinary ventures has supported collaborations between academic laboratories and contract research organizations like Charles River Laboratories and IQVIA, accelerating preclinical development and clinical trial execution.
As with many life-science investors, the firm has faced scrutiny over valuation practices during funding rounds that some critics argue inflate expectations, influencing subsequent public-market performance and patient access debates involving pricing decisions faced by acquirers like Regeneron Pharmaceuticals. Ethical concerns have been raised regarding conflicts of interest in university spinouts tied to faculty equity arrangements at institutions such as Oxford University and Imperial College London. Additionally, participation in high-risk modalities has led to portfolio companies failing in late-stage trials, provoking criticism from patient advocacy groups and commentators focused on capital allocation in the biotechnology sector. Despite these controversies, the firm continues to be a prominent player in financing translational science across global biomedical clusters.
Category:Venture capital firms Category:Biotechnology companies